Meeting
2013 ASCO Annual Meeting
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified liposarcoma.
Authors
Mark Andrew Dickson
Memorial Sloan-Kettering Cancer Center, New York, NY
Mark Andrew Dickson , William D. Tap , Mary Louise Keohan , Sandra P. D'Angelo , Mrinal M. Gounder , Ping Chi , Cristina R. Antonescu , Jonathan Landa , Li-Xuan Qin , Dustin D. Rathbone , Yelena Ustoyev , Aimee Marie Crago , Samuel Singer , Gary K. Schwartz , Mercedes M. Condy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT01209598
Citation
J Clin Oncol 31, 2013 (suppl; abstr 10512)
DOI
10.1200/jco.2013.31.15_suppl.10512
Abstract #
10512
Poster Bd #
5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma.
First Author: Sandra P. D'Angelo
Poster
2020 ASCO Virtual Scientific Program
SAR-096: A phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).
First Author: Sujana Movva
Poster
2018 ASCO Annual Meeting
The association of early toxicity and outcomes for patients treated with abemaciclib.
First Author: Hope S. Rugo
Poster
2023 ASCO Annual Meeting
Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial.
First Author: Nabeel Badri